Abstract:Transcriptional enhanced associate domain (TEAD) proteins bind to YAP/TAZ and mediate YAP/TAZ-induced gene expression. TEADs are not only the key transcription factors and final effector of the Hippo signaling pathway, but also the proteins that regulate cell proliferation and apoptosis. Disorders of Hippo signaling pathway occur in liver cancer, breast cancer, colon cancer and other cancers. S-palmitylation can stabilize the structure of TEADs and is also a necessary condition for the binding of TEADs to YAP/TAZ. The absence of TEAD palmitoylation prevents TEADs from binding to chromatin, thereby inhibiting the transcription and expression of downstream target genes in the Hippo pathway through a dominant-negative mechanism. Therefore, disrupting the S-palmitylation of TEADs has become an attractive and very feasible method in cancer treatment. The palmitate binding pockets of TEADs are conservative, and the crystal structures of TEAD2-palmitoylation inhibitor complexes and the potential TEAD2 inhibitors are more than other TEADs, TEAD2 can be selected to be the target receptor. In this study, structure-based and ligand-based virtual screening, molecular dynamics simulations, Molecular Mechanics Poisson-Boltzmann Surface Area (MM/PBSA) calculations, residue decomposition binding energy calculations, and ADME predictions have been performed to discover 11 potential TEAD2 S-palmitylation inhibitors. ChEBML196567 and ZINC000013942794 are the most recommended, because they formed strong binding energies and stable hydrogen bonds with TEAD2 and have good drugbility and high human oral absorption. We found that it was easier to find the targeting small molecules using a combination of structure-based and ligand-based virtual screening methods. Besides, a new core structure has been found in the selected small molecules. In addition, we analyzed the binding modes of these small molecules to TEAD2, and confirmed the hot spot residues Cys380, Ser345, Tyr426, Phe428, Ile408, and Met379. AVAILABILITY OF DATA AND MATERIAL: Supplementary materials are available online.

Mechanistic insights into peptide and ligand binding of the ATAD2-bromodomain via atomistic simulations disclosing a role of induced fit and conformational selection.

Tumor-Promoting ATAD2 and Its Preclinical Challenges

ATAD2 in Cancer: a Pharmacologically Challenging but Tractable Target

Insight into the key interactions of bromodomain inhibitors based on molecular docking, interaction fingerprinting, molecular dynamics and binding free energy calculation.

Binding Kinetics Versus Affinities in BRD4 Inhibition

Molecular mechanism of inhibitor bindings to bromodomain-containing protein 9 explored based on molecular dynamics simulations and calculations of binding free energies

Binding Mechanism of Inhibitors to BRD4 and BRD9 Decoded by Multiple Independent Molecular Dynamics Simulations and Deep Learning

Theoretical Exploration of the Binding Selectivity of Inhibitors to BRD7 and BRD9 with Multiple Short Molecular Dynamics Simulations

Molecular mechanism study of several inhibitors binding to BRD9 bromodomain based on molecular simulations

A Theoretical Insight into Selectivity of Inhibitors Toward Two Domains of Bromodomain-Containing Protein 4 Using Molecular Dynamics Simulations

Selective Mechanism of Inhibitors to Two Bromodomains of BRD4 Revealed by Multiple Replica Molecular Dynamics Simulations and Free Energy Analyses

A Computational Insight into Binding Modes of Inhibitors XD29, XD35, and XD28 to Bromodomain-Containing Protein 4 Based on Molecular Dynamics Simulations.

Coordination of Di-Acetylated Histone Ligands by the ATAD2 Bromodomain

Discovering inhibitors of TEAD palmitate binding pocket through virtual screening and molecular dynamics simulation

Discovery of a hidden transient state in all bromodomain families

Deciphering the mechanisms of selective inhibition for the tandem BD1/BD2 in the BET-bromodomain family.

Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery

Unveiling Allosteric Regulation and Binding Mechanism of BRD9 through Molecular Dynamics Simulations and Markov Modeling

Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site

Theoretical Research in Structure Characteristics of Different Inhibitors and Differences of Binding Modes with CBP Bromodomain

Structural and atropisomeric factors governing the selectivity of pyrimido-benzodiazipinones as inhibitors of kinases and bromodomains.